Small Cell Lung Cancer (SCLC) Clinical Trial
Official title:
Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer or Those With Progression on First Line Therapy
The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.
This study is designed as a second-line therapy for patients with histologically or cytologically confirmed small cell lung cancer or small cell cancer from other organs or poorly differentiated neuroendocrine tumors that are treated like small cell cancer. This study is for patients with metastatic or recurrent disease. Eligible patients will receive Nab-Paclitaxel (Abraxane), 100 mg/m2, IV over 30 minutes on Days 1 and 8 of a 21-day cycle followed by Gemcitabine, 1000 mg/m2, IV over 30 minutes on Days 1 and 8 of a 21-day cycle. Participants can continue receiving Nab-Paclitaxel and Gemcitabine until disease progression, unacceptable toxicity or withdrawal from the study. Tumor measurements will be done every 2 cycles. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05652686 -
A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3 (the SKYBRIDGE Study)
|
Phase 1 | |
| Recruiting |
NCT05027100 -
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
|
N/A | |
| Active, not recruiting |
NCT03708328 -
A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05158491 -
Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05740566 -
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
|
Phase 3 | |
| Completed |
NCT04285866 -
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
|
||
| Completed |
NCT03066778 -
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
|
Phase 3 | |
| Not yet recruiting |
NCT04727853 -
Study of Irinotecan Liposome Injection as Second-line Regimen in Patients With Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Withdrawn |
NCT02030184 -
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
|
Phase 1/Phase 2 | |
| Completed |
NCT03538028 -
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
|
Phase 1 | |
| Withdrawn |
NCT01210131 -
Hypoxia-guided Radiotherapy With Cisplatin-etoposide in Stage I-III : Small Cell Lung Cancer(SCLC)
|
N/A | |
| Terminated |
NCT01904253 -
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy
|
Phase 2 | |
| Terminated |
NCT02934503 -
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
|
Phase 2 | |
| Completed |
NCT02580994 -
Pembrolizumab in Untreated Extensive SCLC
|
Phase 2 | |
| Completed |
NCT03811652 -
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02628067 -
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
|
Phase 2 | |
| Completed |
NCT02069158 -
Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor
|
Phase 1 | |
| Recruiting |
NCT03460977 -
PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
|
Phase 1 |